• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Section Contents Menu

  • Criminal Investigations
    -

    August 1, 2012: Bodybuilding.com, LLC and DeLuca Brothers Sentenced for Violating the FDCA

     

    OCI Small Clear Seal 

     


     

     

     

    Food and Drug Administration 
    Office of Criminal Investigations

     


     

     

                 U.S. Department of Justice Press Release

     

     

    For Immediate Release
    August 1, 2012
     

     

     

    United States Attorney

    District of Idaho

    Contact: Pamela Bearg

    Public Information Officer

    Wendy J. Olson

    U.S. Attorney

    Kevin T. Maloney

    Assistant U.S. Attorney

    (208) 334-1211

     

     

    Three Defendants Fined a Total of $8.1 Million

     

    BOISE – U.S. Attorney Wendy J. Olson announced today that Bodybuilding.com, LLC, and Jeremy DeLuca and Ryan DeLuca, both of Eagle, Idaho, received criminal fines totaling $8.1 million for violating the Food, Drug and Cosmetic Act (FDCA).  The company and the DeLucas were charged with misdemeanor counts of introduction and delivery for introduction of misbranded drugs into interstate commerce.

     

    The three defendants appeared this afternoon before Chief U.S. District Judge B. Lynn Winmill in United States District Court in Boise.  Bodybuilding.com, LLC was fined $7 million, the maximum possible fine.  Under federal sentencing law, corporations convicted of violating the Food, Drug and Cosmetic Act can be fined up to twice the gross gain from sales of the misbranded product.  Bodybuilding.com, LLC had gross gain of $3.5 million from misbranded prohormone products, including those specifically identified in the plea agreement.  In addition, Judge Winmill ordered Bodybuilding.com, LLC to serve four years’ probation and to implement a product testing procedure recommended by both parties.

     

    Jeremy DeLuca, 33, the former president and vice president of Bodybuilding.com, LLC, was fined $600,000; $100,000 for each of the misdemeanor counts to which he pled guilty.  Ryan DeLuca, 34, the company’s founder and CEO, was fined $500,000.  Judge Winmill also ordered both defendants to serve three years’ probation.  The defendants’ fines are to be paid in monthly installments during the period of probation.

     

    During the plea hearing, Ryan DeLuca accepted full responsibility and assured the court that Bodybuilding.com would never again engage in such violations.

     

    According to their plea agreements, the defendants admitted that they sold five products misbranded as dietary supplements, when they were actually drugs.  The five products – I Force Methadrol, Nutra Costal D-Stianozol, I Force Dymethazine,  Rage RV5, and Genetic Edge Technologies (GET) SUS500 – were drugs because they contained synthetic anabolic steroids or synthetic chemical “clones” of anabolic steroids that were not dietary supplements, and because they were labeled and promoted as products intended to affect the structure and function of the human body (building muscle mass).

     

    Under the Food, Drug and Cosmetic Act, an individual in a business who has responsibility and authority either to prevent or correct a violation of the FDCA is strictly liable for a misdemeanor criminal violation of the Act, regardless of the extent of his knowledge of the violations.  The DeLucas admit that during the time period charged, they had authority over products offered for sale on the company's webstore.  Court documents show that during 2008 and 2009, an FDA compliance officer at Bodybuilding.com informed the DeLucas that some of Bodybuilding.com, LLC’s products contained ingredients that did not qualify as dietary ingredients.  Court records show that in the first seven and one-half months of 2009, Bodybuilding.com had gross revenue of almost $1.8 million from the sale of products similar to the five products the DeLucas and Bodybuilding.com admitted were improperly sold as dietary supplements.

     

    According to the FDCA, “dietary supplements” must contain one or more “dietary ingredients.”  A “dietary ingredient” is a vitamin; a mineral; an herb or other botanical; an amino acid; a dietary substance for use by man to supplement the diet by increasing total dietary intake; or a concentrate, metabolite, constituent, extract, or combination of one or more of these dietary ingredients.

     

    Bodybuilding.com, LLC, is the largest internet retailer of supplements in the world.  It does not manufacture dietary supplements, but only retails products made by others.

     

    Olson said that today’s sentencings are the end result of a detailed and thorough investigation that included the execution of search warrants in September 2009 at Bodybuilding.com, LLC's Boise warehouse and Meridian headquarters.

     

    “The $8.1 million fines imposed in this case send a clear message that retailers, as well as manufacturers, of products sold as dietary supplements have a clear responsibility under the law to ensure that the products they are selling are indeed dietary supplements, and not synthetic steroids or steroid clones masquerading as dietary supplements,” said Olson.  “The officers of those retailers also now know that they will be held responsible and have an obligation to know what the products they sell contain.”

     

    “Today's sentencing should serve as a reminder and deterrent to those involved in the distribution of products promoted as ‘dietary supplements’ that the FDA-Office of Criminal Investigations will continue working with U.S. Attorneys' Offices to protect consumers, vigorously pursuing and holding accountable those who sell unsafe and illegal products to the unsuspecting public,” said Lisa Malinowski, Acting Special Agent in Charge, FDA-Office of Criminal Investigations, Los Angeles Field Office.

     

    The Food and Drug Administration, Office of Criminal Investigations investigated the case.  Assistant United States Attorney Kevin Maloney and Special Assistant United States Attorney Jim Smith, Associate Chief Counsel of the Food and Drug Administration, prosecuted the case.

    # # # #

     

     
     
     
      
     
     
     
     

    -
    -